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AbstrAct
It is now well established that the enzymes phosphoinositide 3-kinases (PI3Ks) 
have a key role in the development and progression of many cancer types and indeed 
PI3Ks inhibitors are currently being tested in clinical trials. Although eight distinct 
PI3K isoforms exist, grouped into three classes, most of the evidence currently 
available are focused on one specific isoform with very little known about the potential 
role of the other members of this family in cancer. Here we demonstrate that the 
class II enzyme PI3K-C2β is overexpressed in several human breast cancer cell lines 
and in human breast cancer specimens. Our data indicate that PI3K-C2β regulates 
breast cancer cell growth in vitro and in vivo and that PI3K-C2β expression in breast 
tissues is correlated with the proliferative status of the tumor. Specifically we show 
that downregulation of PI3K-C2β in breast cancer cell lines reduces colony formation, 
induces cell cycle arrest and inhibits tumor growth, in particular in an estrogen-
dependent in vivo xenograft. Investigation of the mechanism of the PI3K-C2β-
dependent regulation of cell cycle progression and cell growth revealed that PI3K-C2β 
regulates cyclin B1 protein levels through modulation of microRNA miR-449a levels. 
Our data further demonstrate that downregulation of PI3K-C2β inhibits breast cancer 
cell invasion in vitro and breast cancer metastasis in vivo. Consistent with this, PI3K-
C2β is highly expressed in lymph-nodes metastases compared to matching primary 
tumors. These data demonstrate that PI3K-C2β plays a pivotal role in breast cancer 
progression and in metastasis development. Our data indicate that PI3K-C2β may 
represent a key molecular switch that regulates a rate-limiting step in breast tumor 
progression and therefore it may be targeted to limit breast cancer spread.
INtrODUctION
Regulation of cell proliferation and cell survival 
in breast cancer is a complex interplay between steroid 
hormones, growth factors and their receptors [1]. 
Understanding the signaling pathways involved in these 
processes may help find predictive factors for tumor 
aggressiveness and therapy resistance. Among the 
different pathways activated by growth factors receptors, 
signals transmitted by the phosphoinositide 3-kinase 
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(PI3K)/Akt pathway have proven important for cell 
survival in many cell types [2]. Several lines of evidence 
indicate that an inappropriate activation of the PI3K/Akt 
pathway is linked to the development of cancer and the 
inhibition of this pathway has been shown to facilitate 
apoptosis and to sensitize cells to cytotoxic drugs in 
experimental studies [3, 4]. It is therefore not surprising 
that the PI3K/Akt pathway is currently an attractive target 
for therapeutic strategies. PI3K is a family of enzymes, 
comprising eight mammalian isoforms grouped into three 
classes [5]. The majority of studies on PI3K involvement 
in cancer have been focused so far on members of the 
class I subfamily. A broad range of tumor types, including 
breast cancer, are characterized by activating mutations 
of PIK3CA (the gene encoding for p110α, a member of 
the class I group) and its downstream effector AKT1, as 
well as inactivating mutations of phosphatase and tensin 
homolog (PTEN), the gene encoding the lipid phosphatase 
that counteracts the action of PI3Ks [6]. Class I PI3Ks, 
in particular p110α, have therefore a well-established 
role in cancer development and progression. In contrast, 
the potential role of the class II PI3Ks in cancer has not 
been fully explored, although accumulating evidence now 
suggests that this class may also play a role in cancer 
development [7]. For instance, gene expression profiling 
has revealed an increased expression of the β isoform 
of the class II group (PI3K-C2β) in several cancers 
such as acute myeloid leukemia, glioblastoma and acute 
lymphocytic leukemia [8-10]. Consistent with this, PI3K-
C2β was found to be overexpressed in subsets of tumor 
and cell lines from acute myeloid leukemia, glioblastoma 
multiforme, medulloblastoma and small cell lung cancer 
[11]. It has also been shown that different small cell lung 
cancer cell lines overexpress distinct subsets of class IA 
and II PI3Ks, which results in differences in the signaling 
cascades activated by stem cell factor [12]. Increased 
levels of PI3K-C2β have also been detected in primary 
neuroblastoma tumors and cell lines [11, 13]. Recently, a 
significant association has been observed between a cluster 
of variants located upstream and in the promoter regions of 
PIK3C2B, the gene encoding for PI3K-C2β, and prostate 
cancer risk, especially for familial, early-onset disease 
[14]. In addition, significant recurrent mutations (12.9%) 
have also been found in PIK3C2B in lung cancer [15]. 
Other evidence supporting a role for PI3K-C2β in cancer 
includes our demonstration that activation of this enzyme 
is necessary for lysophosphatidic-dependent migration 
of ovarian and cervical cancer cells [16]. Similarly, it 
was reported that overexpression of PI3K-C2β enhances 
migration of A-431 epidermoid carcinoma cells, while 
overexpression of dominant negative PI3K-C2β reduces 
this process [17]. More recently, it has been shown that 
PI3K-C2β has a key role in neuroblastoma tumorigenesis 
[18]. Taken together, these data suggested that PI3K-C2β 
may play a role in cancer development. Interestingly, 
data also indicated that this isoform may be involved in 
epidermal growth factor signaling [19], but the precise 
physiological role of PI3K-C2β in this context and the 
potential correlation to cancer development have not been 
investigated.
In this study, we demonstrate that PI3K-C2β is 
overexpressed in several human breast cancer cell lines 
and in human breast cancer specimens. Our data indicate 
that PI3K-C2β regulates breast cancer cell growth and 
that PI3K-C2β expression in breast tissues is correlated 
with the proliferative status of the tumor. Furthermore, 
downregulation of PI3K-C2β inhibits breast cancer cell 
invasion in vitro and breast cancer metastasis formation in 
vivo. This establishes PI3K-C2β as a promising target in 
breast cancer progression and in metastasis development. 
rEsULts AND DIscUssION
PI3K-C2β is overexpressed in human breast 
cancer cell lines and regulates breast cancer cell 
tumorigenesis
A Western blotting analysis revealed that the 
expression levels of the class II PI3K isoform PI3K-C2β 
increased in a panel of breast cancer cell lines compared 
to epithelial mammary breast cells (BRE80, HBL 100 
and MCF10A), suggesting that PI3K-C2β expression 
is upregulated in breast cancer cell lines compared to 
‘normal’, immortalized breast cells (Figure 1A). To 
investigate the role of PI3K-C2β, we downregulated the 
levels of the enzyme in human breast cancer cell lines 
MCF7, T47D and MDA-MB-231 using a specific shRNA 
(Figure 1B, 1C). Stable cells containing a control, non-
targeting shRNA (“sh scrambled”) were also generated 
(Figure 1B, 1C). Western blot analyses confirmed 
inhibition of PI3K-C2β protein expression in all cell lines 
(Figure 1B, 1C). Specifically a strong reduction in PI3K-
C2β levels was obtained in one clone of MCF7 cells (clone 
1, Figure 1B), which was subsequently used for all studies 
performed in MCF7 cells. Similarly, expression of PI3K-
C2β was strongly inhibited in T47D and MDA-MB-231 
cell populations expressing the specific shRNA (Figure 
1C). Importantly, no effect on the levels of the class I PI3K 
isoforms p110α, p110β and the class II enzyme PI3K-C2α 
was detected in these cells upon downregulation of PI3K-
C2β (Figure 1C).
We next investigated the effect of PI3K-C2β 
downregulation on cell growth. Anchorage-independent 
growth assessed by soft agar assay was significantly 
reduced in T47D and MCF7 cells lacking PI3K-C2β 
(Figure 1D), indicating that this enzyme is required for 
3D growth of these breast cancer cell lines. To evaluate 
the role of PI3K-C2β in vivo, control MCF7 cells (sh 
scrambled) and MCF7 lacking PI3K-C2β (sh PI3K-C2β) 
were injected orthotopically into the mammary fat pad of 
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Figure 1: PI3K-C2β is overexpressed in human breast cancer cell lines and plays a critical role in breast cancer cell 
tumorigenesis. A.Western blot analysis of PI3K-C2β expression in immortalized breast cell lines and in breast cancer cell lines. Tubulin 
was used as a loading control. B. Expression levels of PI3K-C2β in parental MCF7 (wt) and in the indicated MCF-7 cell lines. Tubulin 
was used as loading control. C. Levels of p110α, p110β, PI3K-C2α and PI3K-C2β in MCF7, T47D and MDA-MB-231 stable cell lines. In 
each set of gels, tubulin was used as loading control. D. Results from soft agar colony formation assays performed in the indicated T47D 
and MCF7 cell lines. Data indicate the number of colonies/well and are means ± s.e.m. of n = 3 independent experiments performed in 
triplicate. *p = 0.025, #p = 0.030 (t-Test, one tailed distribution, paired). E. The indicated MCF7 cells were diluted in medium+Matrigel™ 
and injected into the mammary fat pad of 5 week-old pathogen-free nude mice on day 0. E2 pellets were injected subcutaneously into the 
neck with pellet trochar. Tumors volume was measured after 51 days of implantation. Data are means ± s.e.m. from n = 6 (sh scrambled) 
and n = 16 (sh PI3K-C2β) mice. *p = 0.019 (t-Test, one tailed distribution, two sample unequal variance). F. Control MDA-MB-231 (sh 
scrambled) and MDA-MB-231 lacking PI3K-C2β (sh PI3K-C2β) were injected in the mammary fat pad in female immunodeficient mice. 
Tumor weight was assessed at the indicated days after injection. Values are means ± SD from 9 mice per group. G. sh scrambled and sh 
PI3K-C2β MDA-MB-231 cells were injected subcutaneously in female immunodeficient mice. Tumor weight was assessed at the indicated 
days after injection. Values are means ± SD from 8 mice per group.
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nude mice treated with estrogen pellets. Data indicated that 
downregulation of PI3K-C2β significantly reduced tumors 
volume measured at the end of the experiments (day 51 
after implant, Figure 1E). We then injected sh scrambled 
and sh PI3K-C2β MDA-MB-231 cells in the mammary 
fat pad of nude mice and followed tumors growth. These 
data clearly suggested a reduced tumor growth in mice 
bearing shPI3K-C2β MDA-MB-231 cells compared to 
mice injected with control cells, although differences did 
not reach statistical significance possibly because of high 
variability of tumors volume (Figure 1F). Specifically, at 
the last day of the experiment (73 days following implant), 
the weight of tumors generated by sh PI3K-C2β MDA-
MB-231 was 55% lower than tumors generated by control 
cells (Figure 1F). On the other hand growth curves were 
almost overlapping when the two stable cell lines were 
implanted subcutaneously in mice, suggesting a potential 
role for the tumor microenvironment in PI3K-C2β-
dependent breast cancer development and progression 
(Figure 1G).
Taken together these data reveal a key role for PI3K-
C2β in breast cancer growth in vitro and in vivo, especially 
in an estrogen-dependent in vivo xenograft. 
PI3K-C2β regulates breast cancer cell 
proliferation in vitro and cell cycle progression
To better investigate the specific role of PI3K-C2β 
in breast cancer cell growth, we assessed the effect of 
its downregulation in different experimental conditions. 
Counting of cells in culture incubated in growing media 
[containing phenol red and 10% fetal bovine serum (FBS)] 
indicated that growth of T47D (Figure 2A) and MCF7 
(Figure 2B) cells at early passages was not impaired upon 
downregulation of PI3K-C2β. On the other hand, when 
MCF7 cells were starved in phenol red-free/serum-free 
media for 24h and then stimulated with phenol red/serum 
free media supplemented with 17β-Oestradiol (E2)- or 
heregulin B1 (HER), a clear inhibition of cell proliferation 
was detected in MCF7 lacking PI3K-C2β (Figure 2C, 
2D). No difference was observed between parental cells 
and sh scrambled MCF7 (Figure 2C, 2D). Similarly, cell 
proliferation induced by HER (Supplementary Figure 
S1A) and E2 (Supplementary Figure S1B) was impaired 
in sh PI3K-C2β T47D cells compared to control cells. 
To further investigate the specific role of PI3K-
C2β, MCF7 cells were synchronized by incubation in 
phenol red-free/serum-free media for 24h followed by 
incubation in growing media (Figure 2E). Cell cycle 
analysis indicated that in these experimental conditions 
downregulation of PI3K-C2β increased the percentage 
of cells in the G1 phase while reducing the percentage 
of cells in the G2/M phase of the cell cycle (Figure 2E). 
No difference was detected between sh scrambled and 
parental cells (Figure 2E). Similar results were obtained 
when sh scrambled MCF7 were transiently transfected 
with a specific siRNA targeting PI3K-C2β, incubated 
in phenol red-free/serum-free media for 24h and then in 
growing media for further 24h (Figure 2F) or 48h (Figure 
2G). Efficient downregulation of PI3K-C2β was confirmed 
by Western blot (Figure 2H).
These data indicate that PI3K-C2β regulates 
HER- and E2-induced cell proliferation and cell cycle 
progression.
PI3K-C2β regulates cyclin B1 expression
To gain further insight into the mechanisms of 
the PI3K-C2β-dependent regulation of cell proliferation 
and cell cycle we then analyzed the activation of several 
signaling molecules involved in these processes. No effect 
on the activation of several components of the “classical” 
class I PI3K pathway, including Akt (Supplementary 
Figure S2A), 3-phosphoinositide dependent protein 
kinase 1 (PDK1), and the downstream effectors glycogen 
synthase kinase (GSK3)β (Supplementary Figure S2B), 
mechanistic target of rapamycin (mTOR) and S6 kinase 
(S6K) (Supplementary Figure S2C) was detected in 
MCF7 and T47D cells upon PI3K-C2β downregulation. 
Importantly, we observed that HER- and insulin-like 
growth factor-1 (IGF-1)-induced phosphorylation of 
PDK1, Akt, S6K, GSK3β and ERK1/2 was not affected 
by PI3K-C2β downregulation in MCF7 and T47D 
(Supplementary Figure S2D). Similarly, downregulation 
of PI3K-C2β in these cells did not impair Akt and ERK 
phosphorylation upon stimulation with insulin, HER and 
E2 (Supplementary Figure S2E). These data indicate that 
the reduced proliferation of sh PI3K-C2β MCF7 and T47D 
upon HER or E2 stimulation is not due to impairment in 
the activation of MAPK or classical PI3K/Akt pathways. 
On the other hand, Western blot analysis indicated that 
downregulation of PI3K-C2β strongly reduced the protein 
expression levels of cyclin B1 in MCF7 (Figure 3A) and 
T47D cells (Figure 3B). The effect was specific for cyclin 
B1 since no reduction in the expression levels of cyclin 
D1 and cyclin D2 was detected in these cells (Figure 3A, 
3B). Reduced levels of cyclin B1 were also observed in 
MCF7 and T47D upon transient downregulation of PI3K-
C2β using two distinct siRNAs (Figure 3C), ruling out 
any potential aspecific effect due to the chronic PI3K-C2β 
downregulation. Furthermore, cyclin B1 but not cyclin D1 
protein levels, were also reduced in stable MDA-MB-231 
lacking PI3K-C2β (Supplementary Figure S3A). 
Taken together these data indicate that PI3K-C2β 
regulates cyclin B1 expression levels in breast cancer 
cells. 
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Figure 2: PI3K-C2β regulates breast cancer cell proliferation and cell cycle progression. A., B. The indicated T47D (A) 
and MCF7 (B) cells were incubated in normal growing media and counted at the indicated days. Data are means ± s.e.m. from n = 4 (A) 
and n = 3 (B, except for day 4 n = 2) independent experiments. C., D. The indicated MCF7 cell lines were plated in 6 well plates. After 
24h cells were incubated in phenol red-free/serum free (SF) medium for further 24h before incubation in phenol red-free/serum free media 
containing 10nM E2 or 50ng/ml HER. Cell growth was assessed by cell counting at the indicated days. Data are means ± s.e.m. from at 
least n = 3 independent experiments. E. Results from cell cycle analysis performed by FACS in the indicated cell lines. Data are means ± 
s.e.m. from at least n = 3 independent experiments. F. sh scrambled MCF7 cells were transfected with a non targeting siRNA (si scrambled), 
siRNA specifically targeting PI3K-C2β or transfection reagent alone (control, ctr). The following day cells were incubated with phenol 
red-free/serum-free media for 24h and then incubated for further 24h with growing media. Data indicate results from FACS analysis from 
n = 4 independent experiments (apart from si scrambled, n = 3). **p = 0.0028 vs si scrambled (t-Test, one tailed distribution, two sample, 
unequal variance) ##p = 0.0084 vs control (t-Test, one tailed distribution, paired). G. sh scrambled MCF7 cells were transfected and starved 
as in F and then incubated for 48h with growing media. Data indicate results from FACS analysis from n = 5 independent experiments. 
***p = 0.00056 vs si scrambled, ##p = 0.0013 vs control (t-Test, one tailed distribution, paired). H. Representative blot of PI3K-C2β levels 
in lysates from sh scrambled MCF7 cells transfected with non targeting siRNA (si scrambled) and a specific siRNA targeting PI3K-C2β. 
Tubulin was used as loading control.
Oncotarget18330www.impactjournals.com/oncotarget
PI3K-C2β regulates cyclin B1 via miR-449 
regulation
We next sought to assess the mechanism by 
which PI3K-C2β regulates cyclin B1 expression. The 
observation that cyclin B1 mRNA levels were not altered 
in cells lacking PI3K-C2β compared to control cells 
(Supplementary Figure S3B), led us to hypothesize a 
potential role for microRNAs (miRs) in the PI3K-C2β-
dependent regulation of cyclin B1 expression. To test this 
hypothesis, we first performed miR expression profiling 
in the stable T47D cell lines. This analysis revealed a 
selective upregulation of 16 miRs in T47D cells lacking 
PI3K-C2β compared to control cells, including 5 miRs 
belonging to the same family: miR-449a, miR-449b, miR-
34b, miR-34b*, miR-34c-5p (Figure 3D). Interestingly, 
members of the miR-34 family have been shown to 
Figure 3: PI3K-C2β regulates cyclin B1 expression through modulation of miR-449a. A., B. Protein expression levels of 
cyclin D1, cyclin D2 and cyclin B1 in the indicated stable MCF7 and T47D cell lines assessed by Western blotting analysis. Downregulation 
of PI3K-C2β was also confirmed in these lysates. ERK2 and Actin were used as loading control. C. MCF7 and T47D were transiently 
transfected with the indicated siRNAs. Efficient downregulation of PI3K-C2β as well as expression levels of cyclin B1 were assessed by 
Western blotting at 72 h post transfection. GAPDH was used as loading control. D. Log-fold change (LogFc) values of the indicated miRs 
as assessed by miRs Array (Agilent platform) showing increased levels in T47D cells lacking PI3K-C2β compared to control, sh scrambled 
cells. E.-G. The indicated cell lines were transfected with a specific anti miR-449a or a non targeting anti miR (anti miR-ctr). Graphs show 
levels of miR-449a in the corresponding stable cells at 72h following transfection with the indicated anti miRs. Data shown are means ± ± 
s.e.m. from at least n = 3 independent experiments. Representative Western blots show the protein levels of PI3K-C2β and cyclin B1 in the 
corresponding cells. GAPDH was used as loading control. H. sh scrambled MCF7 cells were transfected with mimic miR449a (100nM), 
negative control miR (miR-ctr) or transfection reagent alone (control). Cells were then incubated with phenol red-free/serum free medium 
for 24h before incubation in growing medium for 24h. Data from FACS analysis are from n = 3 independent experiments (except for control 
n = 2). *p = 0.037 vs si scrambled (t-Test, one tailed distribution, paired).
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regulate cyclin B1 levels [20, 21] therefore, they could 
potentially be involved in the PI3K-C2β-mediated 
regulation of cyclin B1. To investigate this hypothesis, 
we first analyzed miRs levels in T47D stable cell lines by 
q-PCR to validate the results of the array. This analysis 
not only confirmed a very significant increase in the levels 
of miR-449a upon PI3K-C2β downregulation, but it also 
indicated that the levels of this specific miR were much 
higher than the levels of the other miRs investigated 
(Supplementary Figure S3C). Upregulation of miR-34b 
(Supplementary Figure S3D), miR-34c (Supplementary 
Figure S3E) and miR-449b (Supplementary Figure S3F) 
was also confirmed in T47D lacking PI3K-C2β compared 
to control cells, although the levels of these miRs were 
much lower compared to the levels of miR449-a. Taken 
together these data indicated that PI3K-C2β regulates miR 
levels, in particular it down modulates miR-449a levels.
To determine whether the PI3K-C2β-mediated 
regulation of miR-449a was associated with modulation of 
cyclin B1 protein expression, we then analyzed the effect 
of miR-449a downregulation on cyclin B1 expression. 
Transfection of T47D (Figure 3E), MDA-MB-231 
(Figure 3F) and MCF7 (Figure 3G) with a specific anti 
miR-449a successfully reduced the levels of miR-449a in 
all cell lines (graphs in Figure 3E-3G). More importantly, 
transfection with the specific anti-miR-449a resulted 
in increased cyclin B1 protein expression, in particular 
in cells lacking PI3K-C2β (Figure 3E-3G). In addition, 
transfection of sh scrambled MCF7 cells with miR-449a 
increased the percentage of cells in G1 phase of the cell 
cycle assessed upon starvation in phenol red-free/serum-
free media and incubation in growing media for 24h 
(Figure 3H), consistent with data obtained upon PI3K-C2β 
downregulation (Figure 2E-2H). 
These data indicate that downregulation of PI3K-
C2β reduces cyclin B1 levels through upregulation of 
miR-449a and that miR-449a is involved in the regulation 
of cell cycle progression.
miR-449a levels are downregulated in primary 
human breast cancer samples
To determine whether modulation of miR-449a 
levels occurs in human breast cancer specimens, we 
analyzed two independent datasets of primary human 
Figure 4: PI3K-C2β modulates phosphorylation of specific proteins. A. Images from Proteome Profiler Human Phospho-Kinase 
Array assay performed in stable MDA-MB-231 cells kept in serum. B.,C. Densitometry analysis of the phospho array. For each protein 
data show values from sh PI3K-C2β samples expressed as fold change compared to corresponding values from sh scrambled samples. 
D.Western blotting analysis of mTOR and S6K phosphorylation at their residues Ser2448 and Thr389 respectively. Membranes were then 
stripped and re-incubated with anti mTOR and anti S6K antibodies. E.,F. Western blotting analysis of STAT3 phosphorylation at its residues 
Tyr705 and Ser727. Tubulin was used as loading control.
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breast cancers, publicly available on Array Express. As 
shown in Supplementary Table S1, with reference to the 
E-GEOD-19783 dataset, we observed that the expression 
of miR-449a was significantly downregulated in basal 
compared to LUM A and normal-like samples (logFC 
-0.9 and -0.4, respectively, p-value < 0.01), and in TP53 
mutated samples versus TP53 wild-type ones (logFC 
-0.5, p-value < 0.01). Analysis of the E-GEOD-12848 
dataset confirmed the downregulation of miR-449a 
(Supplementary Table S1) in basal-like samples compared 
to LUM A ones, and in TP53 mutated versus TP53 wild-
type cancers. Additional information on tumor grade 
revealed that the expression of miR-449a was significantly 
repressed in grade 3 tumors when compared to grade 
1-2 tumors. A similar down-regulation, although not 
statistically significant, was observed for miR-449a in 
T3-T4 samples versus T1 ones (Supplementary Table 
S1). Taken together these data indicate that miR-449a 
is downregulated in human breast cancer tissues and 
negatively associated to aggressiveness/progression.
β catenin is involved in miR-449a regulation in 
MDA-MB-231 cells
To gain further insight into the signaling pathways 
involved in the PI3K-C2β-dependent regulation of miR-
449a and cyclin B1, we then performed a phosphokinase 
array, monitoring phosphorylation and activation of 
~50 proteins in the stable MDA-MB-231 cell lines 
(Figure 4A-4C). Densitometry analysis indicated that 
downregulation of PI3K-C2β selectively affected 
phosphorylation/activation of specific proteins (Figure 
4B, 4C). Western blotting analysis to validate some of the 
phosphoarray results revealed only a partial inhibition of 
mTOR phosphorylation at Ser2448 and no inhibition of 
S6K phosphorylation at Thr389 in MDA-MB-231 upon 
downregulation of PI3K-C2β (Figure 4D), consistent 
with data obtained in MCF7 and T47D (Supplementary 
Figure S2C). The transcription factor Signal transducer 
and activator of transcription 3 (STAT3) was amongst the 
proteins whose phosphorylation was reduced in sh PI3K-
C2β MDA-MB-231 compared to control cells, according 
to the results from the phosphoarray (Figure 4C). Further 
Western blot analysis confirmed that phosphorylation of 
STAT3 at both Tyr705 and Ser727 was indeed inhibited 
upon PI3K-C2β downregulation in MDA-MB-231 cells 
(Figure 4E, 4F). Analysis of the phosphoarray further 
revealed a specific downregulation of β catenin in 
shPI3K-C2β MDA-MB-231 (Figure 4B). Validation of 
the phosphoarray by Western blotting analysis confirmed 
reduced levels of active β catenin in MDA-MB-231 
lacking PI3K-C2β (Figure 5A). To determine whether 
the PI3K-C2β-dependent regulation of β catenin was 
involved in the regulation of miR-449a and cyclin B1, 
TRANSFAC was used to identify transcription factors 
with putative binding sites within 10K bases upstream 
the miR-449a TSS. Factors with either core match and 
matrix match equal 1 were further selected. 90 putative 
binding sites were found with core match and matrix 
match equal 1, 35 of which had negative orientation 
(as miR-449a). Among those 35, 5 corresponded to the 
transcription factor Lymphoid enhancer-binding factor-1 
(LEF1). Since T-cell factor /LEF transcription factors are 
responsible for the vast majority of β catenin signaling 
outputs [22, 23], we then determined whether PI3K-C2β 
was also involved in LEF1 regulation. Western blotting 
analysis indicated that LEF1 protein expression levels 
were indeed downregulated in MDA-MB-231 lacking 
PI3K-C2β (Figure 5B), suggesting that PI3K-C2β 
could regulate miR499a by modulating the β catenin/
LEF1 pathway. To investigate this hypothesis, we next 
determined the effect of β catenin downregulation on 
miR-449a levels. Transient downregulation of both β 
catenin and PI3K-C2β in MDA-MB-231 (Figure 5C) 
significantly increased the levels of miR-449a (Figure 5D). 
Consistent with the observed upregulation of miR-499a, 
transient downregulation of β catenin reduced cyclin B1 
protein levels in MDA-MB-231 (Figure 5E), as observed 
in cells lacking PI3K-C2β (Supplementary Figure S3A). 
Furthermore, downregulation of β catenin in sh scrambled 
MDA-MB-231 induced a very slight, albeit significant 
increase in the percentage of cells in G1 phase of the cell 
cycle assessed upon starvation in phenol red-free/serum-
free media followed by incubation with growing media for 
24h (Figure 5F). 
Taken together these data indicate that β catenin is 
involved in the PI3K-C2β-dependent regulation of miR-
449a and cyclin B1 levels in MDA-MB-231 cells.
It must be noted that downregulation of β catenin 
(Supplementary Figure S4A) did not affect cell cycle 
progression in sh scrambled MCF7 cells, assessed 
following 24h (Supplementary Figure S4B) or 48h 
(Supplementary Figure S4C) reintroduction of growing 
media. This would be consistent with reported data 
indicating a role for β catenin in MDA-MB-231 but not 
in MCF7 cells [24]. We therefore investigated whether 
STAT3 was involved in the regulation of cell cycle in sh 
scrambled MCF7 cells. Data showed that downregulation 
of STAT3 in these cells (Supplementary Figure S4D) 
did not impair cell cycle progression assessed by FACS 
analysis upon 24h starvation in phenol red-free/serum-free 
media followed by 24h (Supplementary Figure S4E) or 
48h (Supplementary Figure S4F) incubation in growing 
media. These data indicate that STAT3 does not play a 
major role in the PI3K-C2β-dependent mechanism of cell 
cycle progression in MCF7 cells.
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Figure 5: PI3K-C2β regulates miR449a/cyclinB1 through modulation of LEF1/β catenin pathway in MDA-MB-231 
cells. A.,B. Western blotting analysis of active β catenin (A) and LEF1 protein levels (B) in the indicated MDA-MB-231 stable cell lines. 
Tubulin was used as loading control and levels of PI3K-C2β were also assessed. C., D. MDA-MB-231 cells were transiently transfected 
with specific siRNAs targeting β catenin and PI3K-C2β respectively. A non targeting (si scrambled) siRNA was used as control. Efficient 
downregulation of the proteins was determined after 48h. Graph shows the effect of transient transfection with the indicated siRNAs on 
miR-449a levels. Data are expressed as fold change over miR-449a/RNU48 values in cells transfected with non targeting siRNA and are 
means ± s.e.m. of n = 4 (si scrambled, si β catenin) and n = 3 (si PI3K-C2β) independent experiments. *p = 0.012, #p = 0.026 (t-Test, one 
tailed distribution, paired). E. Western blotting analysis of cyclin B1 protein levels in MDA-MB-231 at 48h and 72h following transfection 
with the indicated siRNAs. F. MDA-MB-231 cells were transiently transfected as before. Cells were incubated for 24h in phenol red-free/
serum-free medium before further incubation for 24h in growing medium. Data are means ± s.e.m. of n = 3 independent experiments. *p = 
0.024 (t-Test, one tailed distribution, paired). 
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PI3K-C2β regulates senescence via miR-449 
regulation
It has been recently shown that miR-449 induces 
cell senescence in prostate and gastric cancer cells 
[25, 26]. Interestingly, we observed increased cell 
size in both MCF7 (Supplementary Figure S5A) and 
T47D (Supplementary Figure S5B) lacking PI3K-C2β. 
Increased levels of the senescence marker β-galactosidase 
were also observed in both cell lines upon PI3K-C2β 
downregulation (Supplementary Figure S5C) and reduced 
levels of SIRT1 were detected in MCF7 lacking PI3K-C2β 
(Supplementary Figure S5D), suggesting that PI3K-C2β 
Figure 6: PI3K-C2β regulates cell invasion and metastasis formation. A., B. Representative images and results from invasion 
assays performed in the indicated stable MDA-MB-231 cell lines. Graph indicates the number of invaded cells/field expressed as fold 
increase over control (sh scrambled cells) and are means ± s.e.m. from n = 8 independent experiments. ***p = 8.71*10-6 (t-Test, one 
tailed distribution, paired). In these experiments the average number of invaded cells/field was 345±79 (sh scrambled) and 214±52 (sh 
PI3K-C2β). C. Cells were plated as for invasion assays, serum starved overnight and then re-plated for further 48h. Data are expressed as 
fold change over control (sh scrambled cells) and are means ± s.e.m. from n = 6 independent experiments. *p = 0.029 (t-Test, one tailed 
distribution, paired). D. sh scrambled MDA-MB-231 cells were transfected with mimic miR-449a, negative control miR (miR-ctr) or 
transfection reagent alone (control, ctr). The following day cells were starved overnight and then detached for invasion assay, as described 
in the Methods. Graph indicates the number of invaded cells/field expressed as fold increase over control cells and are means ± s.e.m. from 
n = 5 independent experiments (except for miR-ctr, n = 4). **p = 0.0031 vs control (t-Test, one tailed distribution, paired), #p = 0.029 vs 
miR-ctr (t-Test, one tailed distribution, two sample unequal variance). In these experiments the average number of invaded cells/field was 
445±48 (control), 207±80 (miR-449a) and 429±80 (miR-ctr). E. sh scrambled MDA-MB-231 cells were transfected and starved as in D. 
Results from cell counting performed at the start of invasion assays, i.e. 48h after transfection. Data are expressed as fold change over 
control cells and are means ± s.e.m. from n = 5 independent experiments. **p = 0.0067 vs control, #p = 0.015 vs miR-ctr (t-Test, one tailed 
distribution, paired). F. sh scrambled MDA-MB-231 cells were transfected and starved as in D. Results from cell counting performed at the 
end of the invasion assays. Data are expressed as fold change over control cells and are means ± s.e.m. from n = 5 independent experiments 
(except for miR-449a, n = 4).*p = 0.013 vs control, #p = 0.035 vs miR-ctr (t-Test, one tailed distribution, two samples unequal variance). 
G., H. Survival curve of mice injected intravenously with the indicated stable MDA-MB-231 cell lines. Each group consisted of 8 mice. 
The median survival in days for the two groups is also shown. The statistical difference in survival (p = 0.0005) was calculated using the 
Log-rank test.
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may have a role in senescence regulation. To determine 
whether this PI3K-C2β-mediated regulation of cellular 
senescence was dependent on miR-449a regulation, we 
next investigated the effect of miR-449a downregulation 
on SIRT1 levels. Data showed that downregulation 
of miR-449a (performed in parallel with experiments 
presented in Figure 3G) was indeed able to counteract the 
effect of PI3K-C2β downregulation on SIRT1 levels and 
to increase SIRT1 protein levels (Supplementary Figure 
S5D). Furthermore, analysis of cellular proliferation by 
cell counting showed growth impairment in MCF7 and 
T47D lacking PI3K-C2β when kept in culture for more 
than 10 passages (Supplementary Figure S5E, S5F).
PI3K-C2β regulates cell invasion and in vivo 
metastasis formation
Data so far indicated that PI3K-C2β has a key role 
in breast cancer growth both in vivo and in vitro. Since 
PI3K-C2β has previously been involved in cancer cell 
migration [16, 17], we next investigated the potential role 
of PI3K-C2β in cell invasion and metastasis using the 
highly invasive breast cancer cell line MDA-MB-231. As 
shown in Figure 6A, 6B, stable PI3K-C2β downregulation 
indeed affected MDA-MB-231 cell invasion. The effect 
was primarily due to a defect in invasion, as counting of 
cells plated in parallel and incubated in 10% FBS for 48h 
revealed only a slight reduction in cell number (Figure 
6C). Since it was previously reported that β catenin plays 
a role in MDA-MB-231 cell migration [27] and our data 
indicated that both PI3K-C2β and β catenin regulate miR-
449a levels, we then investigated whether miR-449a was 
also involved in cell invasion. Transfection of sh scrambled 
MDA-MB-231 cells with mimic miR-449a significantly 
reduced cell invasion whereas a control miR had no effect 
(Figure 6D), indicating a role for the PI3K-C2β-dependent 
regulation of miR-449a in invasion of MDA-MB-231 
cells. To assess whether cell proliferation was also affected 
in the same experimental conditions, transfected cells were 
starved overnight, detached and counted (Figure 6E). Cells 
were then re-plated in growing media and counted after 
48h (i.e. the duration of the invasion assay, Figure 6F). 
These data showed that transfection of mimic miR-449a 
Figure 7: Expression of PI3K-C2β in breast tissues. A. Representative staining pattern of PI3K-C2β expression in TDLU from 
a non-neoplastic breast tissue, a primary breast cancer and matching metastasis. Panels on the right show magnifications of images 
presented in the corresponding left panels. Scale bars = 20μm. B. Confocal microscopy images of PI3K-C2β (green signal), DRAQ5 (blue 
signal), and their merged signal in a breast cancer tissue. This case shows colocalization of PI3K-C2β expression with DRAQ5 nuclear 
dye. Bright field microscopy image of PI3K-C2β expression on the same case is also shown (original magnification 40x).
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reduced the number of cells (Figure 6E, 6F). However, 
the fact that downregulation of PI3K-C2β did not strongly 
affect cell number in the same experimental conditions 
(Figure 6C) possibly suggests additional roles for miR-
449a in MDA-MB-231 cells. On the other hand, we cannot 
exclude the possibility that the difference may be due to 
different amounts of miR-449a present in sh PI3K-C2β 
cells and in sh scrambled transiently transfected with the 
mimic miR-449a. Nevertheless, data indicate that both 
PI3K-C2β and miR-449a are involved in MDA-MB-231 
cell invasion.
We then investigated the effect of PI3K-C2β 
downregulation in a lung metastasis model in vivo. Data 
indicated that survival of mice injected with sh PI3K-C2β 
MDA-MB-231 cells was significantly increased compared 
to mice injected with sh scrambled cells (Figure 6G, 6H). 
Specifically, we observed that only one mouse out of 8 
mice injected with sh scrambled MDA-MB-231 cells 
was alive at day 59 after implant (Figure 6G). In contrast, 
almost all mice (7 out of 8) injected with MDA-MB-231 
lacking PI3K-C2β were alive at day 59 after implant. The 
difference in survival between the two groups of mice was 
statistically significant (p = 0.0005). These data suggest 
that PI3K-C2β has a key role in breast cancer metastasis 
formation.
To directly investigate the potential role of PI3K-
C2β in metastasis formation, mice injected with sh 
scrambled or sh PI3K-C2β MDA-MB-231 cells were 
sacrificed at the same time point to determine the number 
and size of lung metastases and to evaluate the tumor 
burden of metastasis, as described in the Methods. Images 
of the excised lungs are presented in Supplementary Figure 
S6A. First we observed that at the chosen time point only 
2 out of 8 mice injected with sh PI3K-C2β MDA-MB-231 
cells had developed lung metastases compared to 4 out of 
7 mice injected with sh scrambled cells (Supplementary 
Table S2 and S3). Importantly, the number of metastases 
(Supplementary Figure S6B) and the metastasis burden 
(Supplementary Figure S6C) were clearly reduced in mice 
injected with cells lacking PI3K-C2β, compared to mice 
injected with control cells. A detailed analysis of number/
size of metastases in each mouse and metastasis burden is 
presented in Supplementary Table S2 and S3.
These data indicate that PI3K-C2β is required for 
breast cancer metastasis formation.
Expression of PI3K-C2β in human breast tissues
Once determined the key role of PI3K-C2β in breast 
cancer cells in vitro and in in vivo, we next investigated 
the expression of this enzyme in human non-neoplastic 
breast tissues, primary breast tumors and lymph-node 
metastases. Representative staining patterns of PI3K-C2β 
Table 1: Spearman’s correlation among the indicated markers assessed in primary breast tumors (n=90)
Er PgR Ki-67 PI3K-C2β Cyclin B1 β catenin
pSTAT3
(Y705)
Er
Rho
P 1
0.545
<0.001
-0.121
0.255
0.042
0.696
-0.059
0.581
-0.003
0.980
0.127
0.325
PgR
Rho
P
0.545
<0.001 1
-0.259
0.014
-0.127
0.234
-0.223
0.036
0.296
0.007
0.008
0.953
Ki-67
Rho
P
-0.121
0.255
-0.259
0.014 1
0.330
0.002
0.447
<0.001
-0.111
0.321
0.010
0.941
PI3K-C2β
Rho
P
0.042
0.696
-0.127
0.234
0.330
0.002 1
0.368
<0.001
-0.038
0.735
0.187
0.146
Cyclin B1
Rho
P
-0.059
0.581
-0.223
0.036
0.447
<0.001
0.368
<0.001 1
-0.076
0.503
0.023
0.860
β catenin
Rho
P
-0.003
0.980
0.296
0.007
-0.111
0.321
-0.038
0.735
-0.076
0.503 1
-0.266
0.040
pSTAT3
(Y705)
Rho
P
0.127
0.325
0.008
0.953
0.010
0.941
0.187
0.146
0.023
0.860
-0.266
0.040 1
Rho = Spearman’s coefficient correlation. Significant correlations (P < 0.05) are indicated in bold.
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expression are shown in Figure 7. Whole sections of non-
neoplastic breast tissues, stained with the anti PI3K-C2β 
antibody, revealed a very weak expression of the enzyme 
in the cytoplasm of luminal epithelia of terminal duct 
lobular units (TDLU) and of galactoforous ducts, but not 
in myoepithelia (Figure 7A). On the other hand, PI3K-C2β 
was clearly detectable in 45 out of 90 (50.0%) primary 
breast cancer specimens (Figure 7A), with the proportion 
of tumor cells positive for cytoplasmic PI3K-C2β 
being in the range of 5 to 100% (49.3±5.0, mean±SE). 
A nuclear specific staining was also seen in a smaller 
cell proportion (16.0±6.6, mean±SE). These cells also 
exhibited concomitant cytoplasmic expression of PI3K-
C2β. Confocal microscopy analysis confirmed the nuclear 
localization of PI3K-C2β initially observed by bright field 
microscopy (Figure 7B). Spearman’s correlation (Table 
1) indicated that the expression of PI3K-C2β was directly 
correlated with the proliferative activity, as assessed by 
Ki-67 labeling index (P = 0.002), and with cyclin B1 
expression (P < 0.001). 
When PI3K-C2β expression was analyzed in 
twenty primary tumors/metastases pairs, we observed that 
the percentages of PI3K-C2β positive tumor cells in the 
synchronous lymph-node breast cancer metastases ranged 
from 71 to 100, with a mean±SE of 90.0±1.6, whereas the 
mean±SE percentage of cells positive for PI3K-C2β in the 
corresponding primary tumors was 47.9±9.0. These data 
indicated that metastatic tumors contained statistically 
significantly higher numbers of PI3K-C2β positive cells 
(P < 0.001 by independent samples t-test).
Taken together these data indicate that PI3K-C2β is 
barely detectable in non-neoplastic breast tissues, whereas 
it is clearly expressed in breast primary tumors where it 
correlates with proliferative activity. Furthermore data 
indicate that PI3K-C2β is highly expressed in lymph-node 
breast cancer metastases. 
PI3Ks have been firmly established as key players 
in the development and progression of many cancer types 
and indeed PI3K inhibitors have been developed and are 
currently being tested in clinical trials [4]. One of the 
limitations in our understanding of the contribution of 
PI3Ks to cancer progression comes from the fact that the 
majority of the studies have been selectively focused on 
the involvement of one specific isoform, p110α, which 
is mutated in several cancer types [28]. The potential 
contribution of the other PI3K isoforms to cancer 
development and progression has been mostly disregarded. 
Only recently an increasing interest in understanding the 
role of the distinct PI3K isoforms has emerged [7, 29, 
30]. Based on accumulating evidence suggesting that 
members of the class II subgroup of PI3Ks can have a 
role in cancer [7], here we investigated the potential role 
of the class II isoform PI3K-C2β in breast cancer. We 
detected accumulation of this specific isoform in breast 
cancer cell lines and human breast cancer specimens, 
suggesting a specific role for PI3K-C2β in this cancer 
type. A search in the cBio cancer genomics portal [31, 32] 
indicated that alteration of PIK3C2B has been observed 
by sequencing and copy number analysis of breast cancer 
specimens. Specifically both amplification (Supplementary 
Figure S7A) and point mutations (Supplementary Figure 
S7A, S7B) have been detected. Importantly, Kaplan-
Meier curves for invasive breast cancer cases indicated 
reduced survival in patients with PIK3C2B alteration 
(Supplementary Figure S7C, S7D). These data support the 
conclusion that PI3K-C2β has a key role in breast cancer 
progression and metastasis. Nevertheless, to the best of 
our knowledge our study is the first to actually report 
an increased protein expression of PI3K-C2β in breast 
cancer cell lines, primary breast tumors and corresponding 
lymph-node metastases. 
Our data show that PI3K-C2β is required for breast 
cancer growth both in vitro and in vivo. In particular, 
data suggest that this enzyme may have a key role in 
proliferation induced by growth factors, such as estrogen 
and heregulin that are critical for breast cancer progression. 
Indeed the estrogen-induced in vivo tumor growth was 
inhibited upon orthotopic implantation of sh PI3K-C2β 
MCF7 compared to sh scrambled MCF7 cells. A trend 
towards inhibition of tumor growth was also observed 
upon implantation of sh PI3K-C2β MDA-MB-231 in the 
mammary fat pad, whereas no difference was observed 
when these cells were implanted subcutaneously, possibly 
suggesting a role for the microenvironment in PI3K-
C2β-dependent tumor progression. Consistent with a 
role for PI3K-C2β in breast cancer growth, a significant 
correlation between PI3K-C2β and Ki-67 proliferation 
index was observed in human breast cancer specimens. 
In an effort to identify the mechanisms of the 
specific PI3K-C2β-dependent regulation of cell growth, 
we observed that key signaling pathways were not altered 
in breast cancer cells upon specific downregulation of 
PI3K-C2β. In particular, no difference in Akt activation 
was detected, consistent with our previous observations 
that class II PI3Ks activate distinct signaling pathways 
compared to the well-known class I PI3K/Akt pathway 
[7]. In contrast, we observed that downregulation of PI3K-
C2β reduced cyclin B1 protein expression. Interestingly, 
cyclin B1 expression is known to increase during the G2 
phase of the cell cycle [33] when PI3K-C2β is most active 
[34] supporting the conclusion that PI3K-C2β is involved 
in regulation of cyclin B1 levels. On the other hand, it 
is worth mentioning that a previous study detected cyclin 
B1 in the G1 phase in cells from breast cancer tissues 
[35], which would be consistent with our observation that 
downregulation of PI3K-C2β increases the percentage 
of cells in G1 phase following cellular synchronization. 
Importantly, cyclin B1 protein expression is upregulated 
in many breast cell lines and human mammary tumors 
[33]. Furthermore, cyclin B1 has been found to associate 
with poor prognosis and to be a predictor and classifier of 
outcomes in breast cancer [36, 37]. 
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We further show that PI3K-C2β-dependent 
regulation of cyclin B1 occurs through modulation 
of the specific microRNA miR-449a. Specifically, we 
demonstrate that downregulation of PI3K-C2β increases 
miR-449a levels. To the best of our knowledge this is the 
first demonstration of a role for a class II PI3K isoform in 
miR regulation. miR-449a belongs to the miR-34 family, 
which is expressed at a low level in several cancer cell 
lines and solid tumors including breast cancer [38]. More 
specifically, previous analysis of miRNA expression in 
101 tumor samples from breast cancer patients indicated 
that miR-449a was downregulated in highly proliferative 
samples, with negative correlation with the cell cycle 
genes [38]. Downregulation of miR-449a in breast cancer 
was also confirmed by our analysis of publicly available 
databases. Reduced proliferation [36] and inhibition of 
the BrdU proliferation index [39] was observed in MCF7 
transfected with miR-449a. In particular, these cells 
appeared to be completely arrested in G1 phase in the 
presence of nocodazole [39]. Consistent with these data, 
we observed that transfection of MCF7 cells with mimic 
miR-449a was able to induce G1 arrest, similarly to the 
effect observed upon downregulation of PI3K-C2β.
The specific targets of miR-449 have only been 
partially identified and cyclin B1 is indeed among the 
validated miR-449 targets [25]. Consistent with this, our 
data demonstrate that counteracting the upregulation of 
miR-449a induced by PI3K-C2β downregulation, using 
specific anti miR-449a increases cyclin B1 protein levels.
Our data further identified one of the mechanisms 
by which PI3K-C2β can potentially regulate the levels of 
miR-449a. Specifically, we observed that downregulation 
of PI3K-C2β was associated with reduced activation of β 
catenin in MDA-MB-231 cells and that downregulation 
of β catenin resulted in increased miR-449a levels. These 
data suggest that PI3K-C2β may regulate miR-449a in 
a mechanism involving β catenin activation in MDA-
MB-231 cells. An interesting possibility is that PI3K-C2β 
may specifically regulate the cancer stem cell fraction 
where Wnt signaling plays a major role and therefore 
the observed effect of β catenin/LEF1 in MDA-MB-231 
cells may be due to a reduction in stem cells number. 
There is evidence that indicates an involvement of β 
catenin in miRNA repression [40, 41], even though the 
mechanism by which β catenin downregulates miR-449a 
in breast cancer is currently unknown. Importantly, it 
has been reported that β catenin plays a critical role in 
breast cancer development and tumorigenesis [42] and 
it can be a prognostic marker for breast cancer [43]. On 
the other hand, our data indicate that downregulation of β 
catenin was not able to increase the percentage of MCF7 
cells in G1 phase of the cell cycle, as observed upon 
downregulation of PI3K-C2β or transfection with the 
mimic miR-449a. This is consistent with a previous study 
indicating that inhibition of β catenin/cAMP-responsive 
element-binding protein-binding protein-mediated 
transcription, inhibited cell proliferation in MDA-MB-231 
but not in MCF7 cells [24]. These results suggest the 
existence of additional, β catenin-independent mechanisms 
by which PI3K-C2β modulates miR-449a levels in 
MCF7 cells. Since we observed that PI3K-C2β regulates 
activation of the transcription factor STAT3, which in 
turn can also be involved in miR-34 family regulation 
[44], we then tested whether STAT3 could be involved in 
PI3K-C2β-dependent regulation of miR-449a in MCF7 
cells. However, the observation that downregulation of 
STAT3 did not affect cell cycle progression supports the 
conclusion that STAT3 is not involved in the regulation 
of miR-449a in MCF7 cells. While we cannot completely 
rule out the possibility that downregulation of either β 
catenin or STAT3 could possibly modulate miR-449a 
levels in MCF7 cells in different experimental conditions, 
overall these data suggest that PI3K-C2β modulates miR-
449a levels in MCF7 cells through additional mechanisms 
of regulation. In this respect, it has been reported that miR-
449a levels can be epigenetically repressed by histone H3 
Lys27 trimethylation in MCF7 cells [39]. Furthermore, 
MCF7 ChIP-seq data from the ENCODE project revealed 
the presence of a H3K27me3 peak upstream miR-449a, 
whereas no activating histone modifications were detected 
(data not shown). 
It has been further shown that miR-449a is able 
to inhibit migration and invasion and indeed a recent 
study reported that low expression of miR-449a was 
correlated with lymph-node metastasis [45]. These data 
indicated that miR-449 is a potential tumor suppressor that 
regulates cell cycle, invasion and metastasis by targeting 
multiple oncogenes. Consistent with this, we observed that 
downregulation of PI3K-C2β, as well as transfection of 
cells with mimic miR-449a, inhibited invasion of MDA-
MB-231 cells. More importantly, we observed that survival 
of mice injected with sh PI3K-C2β MDA-MB-231 was 
significantly increased compared to mice injected with sh 
scrambled cells in an in vivo model of lung metastasis. 
Additional experiments revealed a reduced number of 
metastasis and reduced metastasis burden in mice injected 
with cells lacking PI3K-C2β compared to mice injected 
with control cells. These data strongly supported the 
conclusion that PI3K-C2β has a key role in metastasis 
formation induced by highly invasive breast cancer 
cells. Indeed, further analysis of the expression levels of 
PI3K-C2β in twenty primary tumors-metastasis pairs by 
immunohistochemistry analysis revealed that PI3K-C2β 
expression was significantly increased in lymph-node 
metastasis compared to matching primary tumors. 
In summary, in this study we reported that PI3K-
C2β is overexpressed in breast cancer cell lines and 
in human breast tumors and it has a critical role in the 
regulation of breast cancer cell growth. We demonstrated 
that downregulation of PI3K-C2β inhibits breast cancer 
cell invasion in vitro and breast cancer metastasis in 
vivo. Increased levels of PI3K-C2β were also detected 
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in lymph-nodes metastasis compared to primary tumors. 
Data further indicated that PI3K-C2β regulates cyclin 
B1 expression through modulation of miR-449a. In 
addition, we showed that this novel PI3K-C2β/miR-449a 
pathway can also play a key role in the regulation of cell 
invasion. These data demonstrate that PI3K-C2β plays 
a pivotal role in breast cancer progression as well as in 
metastasis formation, and provide a strong rationale for 
the development of compounds that inhibit this PI3K 
isoform as novel potential therapeutic strategies.
mAtErIALs AND mEtHODs
Chemicals and reagents
Human heregulin B1 (HER) and human insulin 
like growth factor-1 (IGF-1) were obtained from 
Peprotec EC Ltd. (London, UK). Human insulin (INS), 
human 17β-Oestradiol (E2), Protease inhibitor cocktail, 
Phosphatase inhibitor cocktail A and Phosphatase inhibitor 
cocktail B were from Sigma-Aldrich (Gillingham, UK). 
BCA Protein Assay kit was from Thermo Scientific Pierce 
(Thermo Fisher Scientific, Inc, Rockford, IL, USA). 
Anti PI3K-C2β, anti PI3K-C2α and mouse anti cyclin 
B1 antibodies were from BD Biosciences (Oxford, UK). 
Rabbit anti cyclin B1, anti cyclin D1, anti cyclin D2, 
rabbit anti phospho Thr202/Tyr204 ERK1/2, anti phospho 
Ser473 Akt, anti phospho Ser2448 mTOR, anti phospho 
Thr389 S6K, anti phospho Ser241 PDK1, anti phospho 
Ser9 GSK3β, anti phospho Tyr705 Stat3, anti phospho 
Ser727 STAT3, anti GSK3β, anti PDK1, anti S6K, anti 
mTOR, anti p110α, anti p110β, anti β catenin were from 
Cell Signaling Technology, Inc. (Danvers, MA, USA). 
Anti Akt, mouse anti phospho Thr202/Tyr204 ERK1/2, 
anti ERK2, anti actin, anti β tubulin, anti LEF-1 were from 
Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). 
Anti active β catenin (that recognises active form of β 
catenin, dephosphorylated on Ser37 or Thr41) was from 
Merck Millipore (Billerica, MA, USA). Anti GAPDH was 
from Abcam (Cambdrige, UK). Anti DRAQ5 was from 
BioStatus (Shepshed, Leicestershire, UK). Horseradish 
peroxidase-conjugated secondary anti-mouse, anti-rabbit 
and anti-goat antibodies were from DAKO UK Ltd. (Ely, 
UK) or from Sigma Aldrich (Gillingham, UK). Enhanced 
chemiluminescence reagent (ECL) was from GE 
Healthcare (Little Chalfont, UK) or Merck Millipore. Non 
targeting siRNA (“si scrambled”) was from Ambion® (Life 
Technologies, Paisley, UK). siRNA targeting PI3K-C2β 
(sequence 1) was from Qiagen (Limburg, Netherlands), 
all other siRNAs were from Dharmacon, Inc. (GE 
Healthcare). Anti miR control and anti-miR-449a were 
from Life Technologies. Unless otherwise stated all other 
reagents were obtained from Sigma-Aldrich.
Cell culture and transfection
The BRE80 cell line was a kind gift from Dr. Maria 
Konstantoulakis (University College London, UK). 
All other cell lines were obtained from American Type 
Culture Collection (ATCC Middlesex, UK). MCF10A and 
BRE80 cell lines were cultured in MEBM® phenol red free 
media, supplemented with MEGM® SingleQuots® (Lonza, 
Walkersville MD). HBL-100, MDA-MB-231, MDA-
MB-468, SKBR-3, MCF7 and T47D cell lines were all 
cultured in DMEM media supplemented with 10% FBS, 
penicillin/ streptomycin, and L-glutamine, all from Life 
Technologies. All cell lines were maintained at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. siRNAs 
and anti miRs were transfected using Oligofectamine™ 
(Life Technologies) or HiPerFect® (Qiagen), according to 
the manufacturer’s instructions. 
Generation of stable cell lines
Specific shRNA targeting PI3K-C2β was designed 
based on a previously validated sequence [16] and 
subcloned into pSuperior vector (Oligogene, Seattle, 
WA, USA). A recombinant pSuperior containing a 
control (scrambled) shRNA was also generated. MCF7 
were transfected using the AMAXA nucleofector 
electroporation system (Lonza, Walkersville, MD, 
USA), following the manufacturer’s standard operating 
instructions. T47D were transfected using Lipofectamine® 
(Life Technologies) according to the manufacturer’s 
instructions. Stable MDA-MB-231 cells were generated 
by retroviral infection, as previously described [46]. 
Single clones (MCF7) and cell populations (T47D, MDA-
MB-231) were selected and maintained in standard media 
with 1µg/ml (MCF7, MDA-MB-231) or 0.5 µg/ml (T47D) 
puromycin. 
Cell growth assays
For cell counting assays, cells were plated into six 
well Nunc multiwell plates at a density of 2 x 105/well for 
MCF7 cells and at 5 x 105/well for T47D. After 24h cells 
were incubated in DMEM/F12-phenol red-free and serum 
-free media supplemented with penicillin/ streptomycin, 
and L-glutamine for further 24h before incubation in 
phenol red-free and serum-free media containing 10nM 
E2 or 50ng/ml HER.
For anchorage-independent growth, a mix of 0.6% 
agarose in DMEM supplemented with 10% FBS was 
allowed to polymerize in a 6 well plate for 30 min. MCF7 
or T47D cells were then resuspended in a mix of 0.3% 
agarose in DMEM supplemented with 10% FBS and 
plated on the 6 well plate. DMEM containing 10% FBS 
was added on top of the second agarose layer and replaced 
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once a week. After 3 weeks, the 6 well plate was incubated 
with 0.0005% crystal violet in methanol overnight and the 
number of colonies was assessed by cell counting.
Cell cycle analysis
MCF7 cells were synchronized by incubation for 
24h in media deprived of serum and phenol red followed 
by 24h or 48h incubation in growing media. After washing 
with PBS, cells were detached, collected and centrifuged 
at 1,200 rpm for 5 minutes. Pelleted cells were fixed in ice-
cold 70% ethanol and re-suspended in 500μl Vindellövs 
Propidium Iodide solution (50 mg/ml). Cells were then 
analyzed by flow cytometry collecting 20,000 events per 
sample using Fluorescence activated cell sorting (FACS) 
Diva software. 
Western blotting analysis of signaling molecules
Activation of signaling molecules was analyzed 
either in cells kept in serum or upon cellular stimulation. 
Where indicated cells were serum deprived for 24h 
in DMEM/F12-phenol red free (Life Technologies), 
supplemented with penicillin/ streptomycin, and 
L-glutamine. Cells were washed with HEPES-buffered 
incubation medium (HBM: NaCl 140 mM, KCl 5 mM, 
NaHCO3 5 mM, MgCl2, 1.1 mM, Na2HPO4 1.2 mM, CaCl2 
1.2 mM, glucose 5.5 mM and HEPES 20 mM, pH 7.4) 
and incubated for 10 min with fresh HBM containing 
10µg/ml INS, 50ng/ml HER, 10ng/ml IGF-1 or 10nM E2. 
HBM was removed, and plates quickly washed with ice-
cold PBS, pH 7.4 (Ca2+-free supplemented with 200 μM 
EGTA) on ice. The cell monolayer was rapidly scraped 
and collected in ice-cold lysis buffer [50 mM Tris, pH 
7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 
mM EGTA, 1µl/ml Protease inhibitor cocktail, 1µl/ml 
Phosphatase inhibitor cocktail A and 1µl/ml Phosphatase 
inhibitor cocktail B] and left for 45 min. Samples were 
then centrifuged at 1000 × g for 5 min at +4°C to remove 
cell debris. The supernatant (crude homogenate) was kept, 
and protein concentration was determined by Bradford 
assay. Alternatively cells were lysed using 2% SDS in 
PBS. Samples were then boiled at 100°C for 5 min in SDS 
sample buffer [62.5mM Tris, 2% SDS, 10% glycerol, 
5% β-mercaptoethanol and 0.002% bromophenol blue]. 
Samples were separated by SDS-PAGE and transferred on 
nitrocellulose membranes by electroblotting. Membranes 
were then incubated in TBS (20 mM Tris, pH 7.5, 150 
mM NaCl) or PBS supplemented with 0.1% (v/v) Tween 
20 (TBS-T, PBS-T) and containing 5% skimmed milk 
powder for 1h at room temperature, followed by overnight 
incubation with primary antibodies at +4ºC. After washing 
with TBS-T or PBS-T membranes were incubated with 
secondary antibodies for 1 h, washed with TBS-T or 
PBS-T and exposed to ECL reagent. When indicated 
membranes were stripped by washing twice for 10 min in 
TBST followed by two 30 min washes in glycine-based 
stripping buffer (1.5% glycine, 0.1% SDS, 1% Tween 
20 pH 2.2). Alternatively membranes were stripped by 
incubation for 30 min at 50ºC in SDS-based stripping 
buffer (62.5 mM Tris HCl pH 6.8, 0.5% SDS, 0.7% β 
mercapthoethanol). 
Human phosphokinase array
Analysis of the phosphorylation status of several 
kinases and proteins was performed using Proteome 
Profiler Human Phospho-Kinase Array Kit (Cat. No. 
ARY003, R&D Systems, Abingdon, UK) according to 
the manufacturer’s instructions. Briefly, stable MDA-
MB-231 cell lines kept in serum were washed in PBS 
and incubated with Lysis Buffer 6 for 30 min at +4ºC. 
Cell debris were removed by centrifugation at 14,000 x 
g for 5 minutes and protein concentration was assessed 
by BCA Protein Assay. After blocking in Array Buffer 1 
for 1h at room temperature each membrane was incubated 
with 600µg of cell lysate overnight at +4ºC. Membranes 
were then washed with 1X Wash Buffer and incubated 
with diluted Detection Antibody Cocktail A and B for 
2h at room temperature followed by incubation with 
Streptavidin-HRP for additional 30 min. Membranes were 
then incubated with Chemi Reagent Mix and exposed on 
an X-ray film for 1-10 minutes. Densitometry analysis 
was performed using Image J software according to the 
manufacturer’s instructions. 
Invasion assay
Assay was performed in MDA-MB-231 stable cell 
lines as previously described [47].
miRs analysis
To assess miRs levels cells were washed twice 
with PBS and lysed using QIAzol Lysis Reagent 
(Qiagen). Total RNA was extracted using miRNAse Mini 
Kit (Qiagen) and cDNA synthesised using TaqMan® 
MicroRNA Reverse Transcription kit (Life Technologies) 
according to manufacturer’s instructions. PCR was 
performed according to manufacturer’s instructions 
(TaqMan®MicroRNA Assays Protocol, Life Technologies). 
Analysis of miRs expression was performed using the 
cycle threshold (Ct) and RNU48 as endogenous control. 
Levels of miRs were obtained using the ∆∆Ct method 
and expressed as 2(-∆∆Ct) values. All experiments were 
performed in triplicate.
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Immunohistochemistry
Tissue microarrays (TMA) were constructed 
by extracting 2-mm diameter cores of histologically 
confirmed invasive breast carcinoma areas from 90 
invasive primary breast tumors, and matching lymph-node 
metastases (n = 20 pairs), as previously described [48]. 
TMA sections were stained using the monoclonal mouse 
anti-human PI3K-C2β at 1:500 dilution for 30 min after 
antigen retrieval performed by two microwave treatments 
at 750 W and 160W for 10 min each in 1M urea buffer 
(pH 8.0). Whole sections of non-neoplastic breast tissues 
from 10 patients were also stained. EnVision kit (Dako, 
Glostrup, Denmark) was used for signal amplification. 
After antigen retrieval by thermostatic bath at 96°C in 10 
mM citrate buffer, pH 6.0 for 40 min sections were also 
incubated with anti-EstogenReceptor-α (ER) MoAb 6F11 
(Menarini, Florence, Italy), anti-Progesteron Receptor 
(PgR) MoAb 1A6 (Menarini), and anti-Ki-67 MoAb MIB-
1 (Dako) for 30 min at room temperature. For β -catenin 
(clone 14/β -catenin, BD Transduction Laboratories, San 
Jose, CA) epitope retrieval was done by microwave heated 
citrate buffer (pH 6.0), and in 1 mmol/L EDTA (pH 8.0) 
for pospho-Stat3 (Tyr705) (clone 3E2, Cell Signaling, 
Danvers, MA). The immunoreactions were revealed 
by a streptavidin-biotin-enhanced peroxidase system 
(Super Sensitive Link-Label IHC DetectionSystem; 
BioGenex, Space, Milan, Italy). For cyclin B1, staining 
was performed using a rabbit monoclonal anti-human 
antibody (clone Y106, Epitomics, Cambridge, UK), at 
1:200 dilution for 30 min, after antigen retrieval performed 
by microwave treatment for 25 min in Tris-EDTA buffer 
(pH 9.0). An anti-rabbit EnVision kit (Dako) was used for 
signal amplification. Positive and negative controls were 
included for each antibody and in each batch of staining. 
Correlation between PI3K-C2β expression and ER, PgR, 
Ki-67, cyclin B1, β-catenin and pospho-Stat3 (Tyr705) 
expressions was assessed by Spearman’s rho correlation. 
The independent samples t-test was used to compare the 
PI3K-C2β expression in primary tumors and matched 
lymph-node metastasis. The SPSS (version 15.0) statistical 
program (SPSS Inc., Chicago, IL) was used for analyses. 
All P values are two-sided; p < 0.05 was considered as 
statistically significant.
For confocal laser-scanning microscopy (LSM 
510 META microscope, Zeiss, Jena, Germany), after 
antigen retrieval, sections were incubated with the 
mouse monoclonal antibody anti PI3K-C2β. Then, Alexa 
Fluor 488 conjugated rabbit anti-mouse IgG (Molecular 
Probes, Eugene, OR) was used (60 min incubation at 
1:200 dilution) for signal detection. Cell nuclei were 
counterstained with DRAQ5 (BioStatus, Shepshed, 
Leicestershire, UK). 
In vivo experiments
Nude immunodeficient mice were obtained from 
Charles River, UK or Harlan-Italy and maintained under 
specific pathogen-free conditions with food and water 
provided ad libitum. All animals in this study were housed 
and sacrificed in accordance with Home Office Guidelines 
and under a project license. Procedures involving 
animals and their care were conducted in conformity 
with institutional guidelines that are in compliance with 
national (Legislative Decree 116 of January 27, 1992, 
Authorization n.169/94-A issued December 19, 1994, by 
Ministry of Health) and international laws and policies 
(EEC Council Directive 86/609, OJL 358. 1, December 
12, 1987; Standards for the Care and Use of Laboratory 
Animals, United States National Research Council, 
Statement of Compliance A5023-01, November 6, 1998). 
Where required, mice were humanely sacrificed via a 
rising concentration of CO2 to near 100% followed by 
cervical dislocation. 
For MCF7 orthotopic experiments cells were diluted 
in 200µl growth medium + 200µl BD Matrigel™ (BD 
Biosciences). The cell suspension was injected into the 
mammary fat pad of 5 week-old pathogen-free nude mice 
on day 0. E2 pellets (1.7mg/pellets, IRA, Sarasota, FL) 
were injected subcutaneously into the neck with pellet 
trochar (IRA). At the end of the experiment tumors volume 
was measured with caliper according to the formula length 
x width x height. 
For experiments with MDA-MB-231 a total 
of 7 x 106 exponentially growing cells were injected 
subcutaneously into the left flank of female 4-week-old 
athymic nude (nu/nu) mice. Eight mice/group were used 
in these experiments. For orthotopic tumor growth, mice 
were anesthetized with a continuous flow of 3% isoflurane/
oxygen mixture. Then, a 1-cm incision in the skin closed 
to the mammary fat pad was performed to expose it, and 
105 cells in a total volume of 10 µl of PBS were injected 
into the mammary gland using an Hamilton® syringe 
equipped with a 26-gauge needle. By exposing the fat pad, 
we were able to ensure that the cells were injected into the 
tissue and not into the s.c. space. Tumor diameters were 
measured with a caliper twice weekly until the animals 
were sacrificed. Tumor weight was derived from tumor 
volume (assuming a density of 1) by the formula: (length 
x width2)/2. Body weights were measured weekly.
To monitor survival in the lung metastasis in vivo 
experiment, 5 x 105 cells were injected i.v. and the animals 
were monitored daily and body weights recorded. At 
symptoms of distress and body weight loss the animals 
were sacrificed and lungs excised. Survival of the animals 
was calculated from the day of cancer cells injection (day 
0) to the day of sacrifice. 
To monitor lung metastasis formation, 5 x 105 cells 
were injected i.v. as above and mice were sacrificed the 
day after the first mouse from group injected with sh 
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scrambled MDA-MB-231 cells died. Lungs were then 
excised and fixed in Bouin’s solution (Bio-Optica). 
Superficial metastatic nodules were counted and 
measured using a dissecting microscope. Specifically 
number of colonies per lung and the diameter of colonies 
were recorded. Metastasis volume was calculated as 
diameter3(mm3)/2, and the lung tumor burden was derived 
from the sum of the volumes of all counted colonies, as 
previously reported [49]. 
miRs array
miRs array was performed at the Genome Centre, 
Queen Mary University of London.
miRs search
MetaCoreTM version 6.10 (GeneGo Inc) was used to 
identify miRs that were likely to target cyclin B1.
Public datasets analysis
Two independent microarray datasets, publicly 
available on Array Express (E-GEOD-19783 and 
E-GEOD-12848), were analyzed for miR expression 
across 101 and 18 primary human breast cancer samples, 
respectively. Samples were stratified according to 
the grade, molecular tumor subtype (Lum A, Lum B, 
ERBB2+, Basal-like, Normal-like), Estrogen Receptor 
status, HER2 status, TP53 status, tumor size, cancer 
staging. For the E-GEOD-19783 dataset, raw data were 
available and the quantile algorithm was used for data 
normalization. For the E-GEOD-12848 dataset, the 
gTotalGeneSignal from GeneView files was used to 
analyze samples. Student T-test p-value and log base 2 
fold change were calculated for each class comparison.
TF binding site analysis
Match tool from TRANSFAC [50] was used for 
identification of transcription factors with putative binding 
sites within 10K bases upstream the miR-449a TSS. The 
weight matrix search was performed using a cut-off that 
minimizes the sum of both false positive and negative 
error rates.
Cellular senescence assay
Cell senescence was assessed using the senescence 
β-galactosidase staining kit from Cell Signaling 
Technology, Inc. according to the manufacturer’s 
instructions.
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